Alzamend Neuro, Inc. (ALZN) [Rocket]

In millions, except per share items	Apr-30-23	Jan-31-23	Oct-31-22	Jul-31-22	Apr-30-22	Jan-31-22	Oct-31-21	Jul-31-21
	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q
Cash flows from operating activities:
Net loss	-3.3	-5.4	-3.1	-3.0	-3.9	-2.6	-3.6	-2.3
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	0.0	0.0	0.0	0.0
Interest expense - debt discount						0.0	0.0	0.0
Gain on extinguishment of debt					0.0
Stock-based compensation to employees and consultants	0.5	1.5	0.7	0.9	1.3	1.1	1.3	0.7
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	0.1	-0.1	0.2	-0.2	0.3	0.3	0.3	-0.2
Accounts payable and accrued liabilities	0.2	2.0	-0.4	-0.1	0.8	-0.6	0.0	0.6
Net cash used in operating activities	-2.2	-1.8	-2.3	-2.5	-1.6	-1.8	-2.0	-1.2

Cash flows from investing activities:
Purchase of machinery					-0.1
Net cash used in investing activities					-0.1

Cash flows from financing activities:
Proceeds from the issuance of common stock and warrants - related party, net					4.0			2.0
Proceeds from stock option exercise					0.0	0.0	0.0	0.0
Payments of related party payable					-0.1
Proceeds from initial public offering, net of underwriters’ discounts and commissions and issuance costs
Net cash provided by financing activities					3.9	0.0	0.0	14.9
Net (decrease) increase in cash	-2.2	-1.8	-2.3	-2.5	2.3	-1.8	-2.0	13.7

Supplemental disclosures of cash flow information:
Non-cash financing activities:
Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party
Conversion of Series A Convertible Preferred Stock
Issuance of common stock on conversion of note
Fair value of warrants issued in connection with initial public offering
Issuance of common stock for related party payable